These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26239729)

  • 1. Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series.
    Weigel JD; Hunfeld NG; Koch BC; Egal M; Bakker J; van Schaik RH; van Gelder T
    Intensive Care Med; 2015 Nov; 41(11):2013-4. PubMed ID: 26239729
    [No Abstract]   [Full Text] [Related]  

  • 2. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
    Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
    Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.
    Bennis Y; Bodeau S; Bouquié R; Deslandes G; Verstuyft C; Gruson B; Andréjak M; Lemaire-Hurtel AS; Chouaki T
    Br J Clin Pharmacol; 2015 Oct; 80(4):782-4. PubMed ID: 26138512
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic testing for the treatment of aspergillosis with voriconazole in two HIV-positive patients.
    Fulco PP; Beaulieu C; Higginson RT; Bearman G
    Pharmacogenet Genomics; 2019 Aug; 29(6):155-157. PubMed ID: 31211761
    [No Abstract]   [Full Text] [Related]  

  • 6. Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?
    Danion F; Jullien V; Rouzaud C; Abdel Fattah M; Lapusan S; Guéry R; Bigé N; Morgand M; Pallet N; Lanternier F; Lortholary O
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
    Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole.
    Klomp SD; Veringa A; Alffenaar JC; de Boer MGJ; Span LFR; Guchelaar HJ; Swen JJ
    Clin Transl Sci; 2024 Jul; 17(7):e13887. PubMed ID: 39010708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure.
    Abidi MZ; D'Souza A; Kuppalli K; Ledeboer N; Hari P
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):46-8. PubMed ID: 25986028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
    Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
    Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected].
    Motta I; Calcagno A; Baietto L; D'Avolio A; De Rosa FG; Bonora S
    Infez Med; 2015 Dec; 23(4):367-9. PubMed ID: 26700090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
    Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
    Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer.
    Wasko JA; Ustun C; Birkenbach M; Faizer R; Green JS
    J Oncol Pharm Pract; 2019 Apr; 25(3):703-705. PubMed ID: 29285995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers.
    Lee SW; Oh J; Kim AH; Ji SC; Park SI; Yoon SH; Chung JY; Yu KS; Jang IJ; Lee S
    Pharmacogenomics J; 2020 Dec; 20(6):792-800. PubMed ID: 32461666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
    Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
    Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
    Mangal N; Hamadeh IS; Arwood MJ; Cavallari LH; Samant TS; Klinker KP; Bulitta J; Schmidt S
    Clin Pharmacol Ther; 2018 Nov; 104(5):957-965. PubMed ID: 29315506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
    Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
    Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Voriconazole dosage optimization in adult patients based on different CYP2C19 genotypes].
    Matsumoto K
    Jpn J Antibiot; 2015 Aug; 68(4):243-7. PubMed ID: 26625537
    [No Abstract]   [Full Text] [Related]  

  • 20. High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.
    Bernal-Martínez L; Alcazar Fuoli L; Miguel-Revilla B; Carvalho A; Cuétara Garcia MS; Garcia-Rodriguez J; Cunha C; Gómez-García de la Pedrosa E; Gomez-Lopez A
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.